By growing mini‑organs from patient biopsy samples, we create high‑throughput drug screens tailored to each individual’s tumor or genetic disease. Integrated genomic and pharmacodynamic analyses will pinpoint optimal therapies. This approach seeks to streamline personalized treatment decisions in clinical settings.

Utilizing CRISPR/Cas9, we edit T cells to boost tumor‑homing receptors and resist inhibitory signals within the tumor microenvironment. Preclinical safety and persistence studies will inform protocol optimization. This translational pipeline aims to advance lead candidates into first‑in‑human trials.